CoChat

Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis

Open access
Miao, Jing, Herrmann, Sandra M · 2023 · Clinical Kidney Journal

The DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and outcomes, leading to an expanding use in millions of patients worldwide. However, they can cause a spectrum of immune-related adverse events (irAEs). Essentially, any organs can be affected by irAEs, which have emerged as therapy-limiting side effects. In the kidneys, ICI-associated acute interstitial nephritis (ICI-AIN) leads to acute kidney injury (AKI) in 2%–5% of patients on ICI therapy. AKI associated with ICI therapy pathologically presents with AIN in nearly 90% of the cases, but the pathophysiology of ICI-AIN remains to be defined. The generation of autoreactive T cells in patients receiving AIN-inducible drugs, such as proton pump inhibitors (PPIs), is one of the leading theories, supported by a higher incidence of ICI-AIN in patients on these AIN-inducible drugs. In this review, we will discuss our understanding of the incidence, potential pathophysiological mechanisms, clinical presentations, risk factors, diagnosis, and management of PPI-related AIN and its interaction with ICI therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ckj/sfad109

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1: Proposed major pathophysiological mechanisms of PPI-related kidney adverse outcomes in the setting of ICI therapy. (a) In addition to the direct toxic damage, one of the most suggested mechanisms is that PPI may act as a hapten. In kidney, PPI can bind to kidney specific tubulointerstitial proteins. The peripherally drug-formed haptens are transported to kidney, and metabolized by tubular epithelial cells. The resultant antigen–antibody complex and/or metabolites are presented to dendritic cells located in kidney interstitial tissue, leading to subsequent T-cell-mediated immune response. (b) In the setting of ICI therapy, anti-CTLA-4 (i.e. ipilimumab) can induce T-cell activation mainly by blocking CD80/CD86 binding to the CTLA-4 receptor, which allows CD28 binding. Blocking PD-L1 binding to PD-1 with anti-PD-1 or anti-PD-L1 monoclonal antibodies (i.e. nivolumab and atezolizumab) promotes tumor cell killing but also activates T cells or suppresses deactivation of T cells. (c) Injured cells produce proinflammatory chemokines and cytokines, which can recruit inflammatory cells and induce fibroblast proliferation related to tubular cell damage (i.e. AIN or subclinical AIN) and further kidney injury (AKI, CKD, and ESKD). CTLA-4: cytotoxic T-lymphocyte–associated antigen 4; PD-1: programmed death 1; PD-L1: PD-ligand-1; CR: complete remission or recovery; EKSD: end-stage kidney disease.
Figure 1: Proposed major pathophysiological mechanisms of PPI-related kidney adverse outcomes in the setting of ICI therapy. (a) In addition to the direct toxic damage, one of the most suggested mechanisms is that PPI may act as a hapten. In kidney, PPI can bind to kidney specific tubulointerstitial proteins. The peripherally drug-formed haptens are transported to kidney, and metabolized by tubular epithelial cells. The resultant antigen–antibody complex and/or metabolites are presented to dendritic cells located in kidney interstitial tissue, leading to subsequent T-cell-mediated immune response. (b) In the setting of ICI therapy, anti-CTLA-4 (i.e. ipilimumab) can induce T-cell activation mainly by blocking CD80/CD86 binding to the CTLA-4 receptor, which allows CD28 binding. Blocking PD-L1 binding to PD-1 with anti-PD-1 or anti-PD-L1 monoclonal antibodies (i.e. nivolumab and atezolizumab) promotes tumor cell killing but also activates T cells or suppresses deactivation of T cells. (c) Injured cells produce proinflammatory chemokines and cytokines, which can recruit inflammatory cells and induce fibroblast proliferation related to tubular cell damage (i.e. AIN or subclinical AIN) and further kidney injury (AKI, CKD, and ESKD). CTLA-4: cytotoxic T-lymphocyte–associated antigen 4; PD-1: programmed death 1; PD-L1: PD-ligand-1; CR: complete remission or recovery; EKSD: end-stage kidney disease.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Cited by

See all 33

Metadata

Authors
Miao, J., & Herrmann, S. M.
Affiliations
Mayo Clinic (US)
Corresponding author
Herrmann, Sandra M
Venue
Clinical Kidney Journal
Published
2023-05-15
Volume
16
Issue
11
Pages
1834-1844
ISSN
  • 2048-8505 (ISSN-L)
  • 2048-8513
OpenAlex
W4382790817
Cited by
31
References
106
Citations by year
2026: 9 · 2025: 8 · 2024: 11 · 2023: 3
FWCI
1.00
Type
journal article
Language
en
Open access
Locations
  • Clinical Kidney Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Korea National Institute of Health (K08 DK118120)
  • NIDDK
  • CCaTS (UL1TR002377)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Keywords
immune checkpoint inhibitors, proton pump inhibitors, acute interstitial nephritis, immune-related adverse events, acute kidney injury, drug-induced nephrotoxicity, autoreactive T cells, pathophysiology, risk factors, diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis. https://app.cochat.ai/papers/10.1093/ckj/sfad109
The paper
Miao, J., & Herrmann, S. M. (2023). Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfad109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.